

---

# Medicare Inpatient Prospective Payment System

---

## Proposed Payment Rule Brief Provided by the Wisconsin Hospital Association

Program Year: FFY 2022

### Overview and Resources

On April 27, 2020, the Centers for Medicare and Medicaid Services (CMS) released the proposed federal fiscal year (FFY) 2022 payment rule for the Medicare Inpatient Prospective Payment System (IPPS). The proposed rule reflects the annual updates to the Medicare fee-for-service (FFS) inpatient payment rates and policies. In addition to the regular updates to wage indexes and marketbasket, this rule includes the following proposals:

- Rebasement and revising the IPPS marketbasket (MB) and the Capital Input Price Index (CIPI) based from FFY 2014 to FFY 2018.
- A rate increase amount (+0.5%) for the Coding Offset adjustment;
- Updates to the Medicare Disproportionate Share Hospital (DSH) payment policies including hospitals would be eligible for DSH payments in FFY 2022 based on audited FFY 2018 S-10 data;
- Repealing the policy requiring hospitals to report the median payer-specific negotiated rates for inpatient services, by MS-DRG, for Medicare Advantage organizations on the Medicare cost report;
- Creation of new GME opportunities for underserved populations;
- Updates to the program rules for the Value-Based Purchasing (VBP), Readmission Reduction Program (RRP) and Hospital-Acquired Condition (HAC) programs; and
- Updates to the payment penalties for non-compliance with the Hospital Inpatient Quality Reporting (IQR) and Electronic Health Record (EHR) Incentive Programs.

Program changes would be effective for discharges on or after October 1, 2021 unless otherwise noted. CMS estimates the overall impact of this proposed rule update to be an increase of approximately \$2.507 billion in aggregate payments for acute care hospitals in FFY 2022. This estimate includes operating, capital, and new technology changes as well as increased graduate medical education (GME) payments and increased payments as a result of the imputed floor provision.

A copy of the proposed rule and other resources related to the IPPS are available on the CMS website at <https://www.cms.gov/medicare/acute-inpatient-pps/fy-2022-ipps-proposed-rule-home-page>. Comments on all aspects of the proposed rule are due to CMS by June 28, 2021 and can be submitted electronically at <https://www.regulations.gov/> by using the website's search feature to search for file code "1752-P".

An online version of the rule is available at <https://www.federalregister.gov/d/2021-08888>

**Note:** Text in italics is extracted from the April 27, 2021 Display copy of the *proposed rule*.

### IPPS Payment Rates

*DISPLAY pages 62 - 64, 840 - 887, 1,152 - 1,155, and 1,663 - 1,742*

The table below lists the federal operating and capital rates proposed for FFY 2022 compared to the rates currently in effect for FFY 2021. These rates include all marketbasket increases and reductions as well as the application of annual budget neutrality factors, including CMS's proposal to rebase the MB and CIPI using FFY 2018 data. These rates do not reflect any hospital-specific adjustments (e.g. penalty for non-compliance under the IQR Program and EHR Meaningful Use Program, quality penalties/payments, DSH, etc.).

	Final FFY 2021	Proposed FFY 2022	Percent Change
<b>Federal Operating Rate</b>	<b>\$5,961.31</b>	<b>\$6,140.29</b>	<b>+3.00%</b>
<b>Federal Capital Rate</b>	<b>\$466.21</b>	<b>\$471.89</b>	<b>+1.22%</b>

The following table provides details for the proposed annual updates to the inpatient federal operating, hospital-specific, and federal capital rates for FFY 2022.

	Federal Operating Rate	Hospital-Specific Rates	Federal Capital Rate
Marketbasket/Capital Input Price Index update	<b>+2.5%</b>		<b>+0.7%</b>
ACA-Mandated Reductions 0.2 percentage point (PPT) productivity reduction	<b>-0.2 PPT</b>		—
MACRA-Mandated <u>Retrospective</u> Documentation and Coding Adjustment	<b>+0.5%</b>	—	—
Wage Index Transition Adjustments	<b>+0.13%</b>		<b>-0.24%</b>
Annual Budget Neutrality Adjustments	<b>+0.06%</b>		<b>+0.76%</b>
<b>Net Rate Update</b>	<b>+3.00%</b>	<b>+2.5%</b>	<b>+1.22%</b>

- **Effects of the Inpatient Quality Reporting (IQR) and EHR Incentive Programs (DISPLAY page 883):** Beginning in FFY 2015, the IQR MB penalty changed from -2.0 percentage points to a 25% reduction to the full MB, and the EHR Meaningful Use (MU) penalty began its phase-in over three years, starting at 25% of the full MB. Beginning FFY 2017, the EHR MU penalty has capped at 75% of the MB; hence the full MB update is at risk between these two penalty programs. A table displaying the various update scenarios for FFY 2022 is below:

	Neither Penalty	IQR Penalty	EHR MU Penalty	Both Penalties
Net Federal Rate Marketbasket Update (2.5% MB less 0.2 PPT productivity)	<b>+2.30%</b>			
Penalty for Failure to Submit IQR Quality Data (25% of the base MB Update of 2.5%)	—	<b>-0.625 PPT</b>	—	<b>-0.625 PPT</b>
Penalty for Failure to be a Meaningful User of EHR (75% of the base MB Update of 2.5%)	—	—	<b>-1.875 PPT</b>	<b>-1.875 PPT</b>
<b>Adjusted Net Marketbasket Update (prior to other adjustments)</b>	<b>+2.30%</b>	<b>+1.675%</b>	<b>+0.425%</b>	<b>-0.2%</b>

- **Rebasing and Revision of the Acute Care Hospital Marketbasket and Capital Input Price Index (CIPI) (DISPLAY pages 842 – 880):** CMS rebases the IPPS MB and CIPI every four years by updating the costs and input price indexes used in the calculation, and may make revisions by changing the data sources for price proxies used in the input price index. The last update to the MB and CIPI was implemented in FFY 2018 using 2014 data as the base period for the construction of the costs.

For FFY 2022, CMS is proposing to rebase the hospital marketbasket and CIPI cost weights using FFY 2018 Medicare cost report data and the 2012 Benchmark Input-Output (I-O) “Use Tables/Before Redefinitions/Purchaser Value” tables published by the Bureau of Economic Analysis (BEA) which are available publicly at [https://www.bea.gov/industry/io\\_annual.htm](https://www.bea.gov/industry/io_annual.htm). Data taken from the BEA file are derived from the 2012 Economic Census, and will be inflated to 2018 values by CMS. In addition, CMS will revise several of the price proxies using Bureau of Labor Statistics (BLS) data.

As a result, CMS proposes to apply a marketbasket update of 2.5% and a CIPI of 0.7% for FFY 2022, which CMS states would be the same if rebasing was not done.

- **Retrospective Coding Adjustment** (*DISPLAY pages 19 and 62 - 64*): CMS is proposing a retrospective coding adjustment of +0.5% to the federal operating rate in FFY 2022 as part of the fifth year of rate increases (of six) tied to the American Taxpayer Relief Act (ATRA). The coding offset rate increase was authorized as part of ATRA, which required inpatient payments to be reduced by \$11 billion over a 4-year period, resulting in a cumulative rate offset of approximately -3.2%.
- **Outlier Payments** (*DISPLAY pages 1,688 – 1,694 and 1,698 – 1,711*): CMS continues to believe that using a methodology that incorporates historic cost report outlier reconciliations to develop the outlier threshold is a reasonable approach and would provide a better predictor for upcoming fiscal year. Therefore, for FFY 2022, CMS is proposing to incorporate total outlier reconciliation dollars from the FFY 2016 cost reports into the outlier model using a similar methodology to FFY 2021.

Analysis done by CMS determined outlier payments at 5.11% of total IPPS payments; CMS is proposing an outlier threshold of \$30,967 for FFY 2022. The proposed threshold is 6.60% higher than the current (FFY 2021) outlier threshold of \$29,064.

- **Stem Cell Acquisition Budget Neutrality Factor** (*DISPLAY page 1,666*): CMS is proposing not to remove the Stem Cell Acquisition budget neutrality factor from the FFY 2021 standard amount and not to apply a new factor as they believe it would not satisfy budget neutrality. CMS intends to consider using cost report data regarding reasonable acquisition costs when it becomes available for future budget neutrality adjustments.

## Wage Index

*DISPLAY pages 778 – 839 and 1,714 – 1,718*

- **CBSA Delineation Updates** (*DISPLAY pages 779 – 784*): CMS is proposing to adopt the revisions from the March 6, 2020 OMB Bulletin 20-01 for the FFY 2022 CBSA-based labor market area delineations under the IPPS. CMS states that the delineation changes within OMB Bulletin 20-01 would not affect the CBSA-based labor market area delineations used under the IPPS. Therefore, specific wage index updates are not necessary as a result of the proposed updates. This bulletin can be found at <https://www.whitehouse.gov/wp-content/uploads/2020/03/Bulletin-20-01.pdf>.

For FY 2021, CMS adopted a 5% cap on any decrease to a hospital's wage index. Due to the COVID-19 public health emergency (PHE), CMS seeks comment on whether the transition, set to expire at the end of FFY 2021, should be extended into FFY 2022 in a budget neutral manner.

- **Imputed Floor** (*DISPLAY pages 803 – 809*): From FFY 2005 through FFY 2018, CMS had adopted and extended a budget neutral imputed floor policy to address concerns from hospitals in all-urban states that felt disadvantaged from not having no rural hospitals, and thus no wage index floor. For FFYs 2019 through 2021 hospitals in all-urban states received a wage index that was calculated without applying an imputed floor. The American Rescue Plan of 2021 established a minimum area wage index for hospitals in all-urban states for FFY 2022 and onward, not implemented in a budget neutral manner, and applied after the application of the rural floor. This imputed floor would be determined by taking the higher of two different methodologies for calculating a minimum wage index.
  - The "original" methodology was established for FFY 2005 where CMS "...calculated the ratio of the lowest-to-highest CBSA wage index for each all-urban State as well as the average of the ratios of lowest-to-highest CBSA wage indexes of those all-urban States. ...then compared the State's own ratio to the average ratio for all-urban States and whichever was higher was multiplied by the highest CBSA wage index value in the State—the product of which established the imputed floor for the State."
  - The "alternative" methodology was established for FFY 2013 to address concerns that the "original" methodology could benefit all-urban states with multiple CBSAs but not benefit an all-urban state with only one CBSA. CMS "...determined the average percentage difference between the post-reclassified, pre-floor area wage index and the post-reclassified, rural floor wage index (without rural floor budget neutrality applied) for all CBSAs receiving the rural floor. The lowest post-reclassified wage index assigned



Area	FFYs 2018 - 2021	Proposed FFYs 2022 - 2025
<b>Alaska:</b>		
City of Anchorage and 80-kilometer (50-mile) radius by foot	1.25	1.22
City of Fairbanks and 80-kilometer (50-mile) radius by foot	1.25	1.22
City of Juneau and 80-kilometer (50-mile) radius by foot	1.25	1.22
Rest of Alaska	1.25	1.24
<b>Hawaii:</b>		
City and County of Honolulu	1.25	1.25
County of Hawaii	1.21	1.22
County of Kauai	1.25	1.25
County of Maui and County of Kalawao	1.25	1.25


A complete list of the proposed wage indexes for payments in FFY 2022 is available on Table 2 on the CMS Web site at <https://www.cms.gov/files/zip/fy2022-ipp-nspr-tables-2-3-4a-4b.zip>

## DSH Payments

*DISPLAY pages 22 – 23, 901 – 957, and 1,822 – 1,828*

The ACA mandates the implementation of Medicare DSH calculations and payments in order to address the reductions to uncompensated care as coverage expansion takes effect. By law, 25% of estimated DSH funds, using the traditional formula, must continue to be paid to DSH-eligible hospitals. The remaining 75% of the funds, referred to as the Uncompensated Care (UCC) pool, are subject to reduction to reflect the impact of insurance expansion under the ACA. This UCC pool is to be distributed to hospitals based on each hospital’s proportion of UCC relative to the total UCC for all DSH-eligible hospitals.

- **DSH Payment Methodology for FFY 2022** (*DISPLAY pages 901 – 950*): The following schematic describes the DSH payment methodology mandated by the ACA along with how the program has been proposed to change from FFY 2021 to FFY 2022:





#### 4. Determine actual DSH eligibility at cost report settlement

- No update to national UCC pool amount or hospital-specific UCC factors (unless merger occurs)
- Recoup both 25% traditional DSH payment and UCC payment if determined to be ineligible at settlement
- Pay both 25% traditional DSH payment and UCC payment determined to be DSH-eligible at settlement, but not prior

The DSH dollars available to hospitals under the ACA's payment formula would decrease by \$662 million in FFY 2022 relative to FFY 2021 due to a decrease in the pool from projected DSH payments.

- **Eligibility for FFY 2021 DSH Payments** (*DISPLAY pages 904 – 909 and 1,822 – 1,828*): CMS is projecting that 2,378 hospitals will be eligible for DSH payments in FFY 2022 based on audited FFY 2018 S-10 data. Only hospitals identified in the final rule as DSH-eligible will be paid as such during FFY 2022. CMS has made a file available that includes DSH eligibility status, UCC factors, payment amounts, and other data elements critical to the DSH payment methodology. The file is available at <https://www.cms.gov/files/zip/fy2022-ipps-nprm-medicare-dsh-supplemental-data-file.zip>
- **Adjustment to Factor 3 Determination** (*DISPLAY pages 923 – 950*): CMS is proposing the continued use of the most recent single year of cost report data that has been audited for a significant number of hospitals receiving substantial Medicare uncompensated care payments to calculate Factor 3 for all eligible hospitals, with the exception of hospitals located in Puerto Rico and Indian Health Service (IHS) and Tribal hospitals.

Similar to the FFY 2021 methodology, for FFY 2022 CMS proposes the use of Worksheet S–10 data from the audited FFY 2018 cost reports to calculate Factor 3.

For the values provided with the FFY 2022 IPPS proposed rule, CMS utilized a HCRIS extract updated through February 19, 2021, except where report upload discrepancies by CMS or the MACs have been corrected. CMS intends to use the March 2021 update for the final rule and [the March update] for all future final rules but may consider using more recent data if appropriate.

Regarding hospitals for which CMS has elected to not use S-10 data in the past:

- **UCC Distributions for Indian Health Service (IHS) and Tribal Hospitals:** As in prior years, CMS is proposing not to utilize Worksheet S-10 for the calculation of Factor 3 for IHS/Tribal hospitals. Instead, Factor 3 amounts for these providers would be calculated by utilizing the FFY 2013 data for Medicaid days, due to the effects of Medicaid expansion on data reported for FFYs 2014 and 2015, which would then combined with the most recent update of the SSI days. The denominator for these hospitals' Factor 3 determination would continue to be based on low-income patient days.
- **UCC Distributions for Puerto Rico Hospitals:** For FY 2022, CMS proposes to use the same methodology finalized in FFY 2021 to determine Factor 3 for Puerto Rico hospitals based on FFY 2013 Medicaid days and the most recent update of SSI days, with a denominator based on low-income patient days. In addition, as residents of Puerto Rico are not eligible for SSI benefits, CMS also proposes to continue using a proxy for SSI days for Puerto Rico hospitals, consisting of 14 percent of a hospital's Medicaid days.

CMS is proposing to modify the use of a hospital's three-year average discharge number to estimate their uncompensated care payment per discharge. CMS believes that using a three-year average which includes FFY 2020 discharge data would underestimate discharges due to the COVID-19 pandemic effecting number of discharges. Instead, CMS proposes to use a two-year average of discharges to calculate interim payments (FFY 2018 and FFY 2019). As in past years, interim payments made using this value will be reconciled at cost report settlement to equal the uncompensated care pool distribution amount that will be published with the FFY 2022 IPPS final rule.

For FY 2022, CMS is proposing that hospitals would have 60 days from the public display of the FFY 2022 IPPS proposed rule and 15 business days from the date of public display of the FFY 2022 IPPS PPS final rule to review and submit comments on the accuracy of the table and supplemental data file published along with the respective rules. Comments regarding issues that are specific to data and supplemental data files for this proposed rule can

be submitted to [Section3133DSH@cms.hhs.gov](mailto:Section3133DSH@cms.hhs.gov). Any changes to distribution amounts will be posted on the CMS website prior to October 1, 2020.

- **Counting Days Associated with Section 1115 Demonstration Projects in the Medicaid Fraction** (*DISPLAY pages 950 – 957*): Due to a number of court decisions regarding the inclusion of patient days in the numerator of the Medicaid fraction when calculating a hospital's disproportionate patient percentage, CMS is proposing that for a patient day to be included in the numerator, the patient must be eligible for inpatient hospital services under an approved state Medicaid plan that includes coverage for inpatient hospital care on that day or directly receives inpatient hospital coverage on that day under an authorized waiver.

## GME Payments

*DISPLAY pages 899 – 900 and 1,068 – 1,134*

The Consolidated Appropriations Act (CAA) of 2021 contained 3 provisions, each in a different section, affecting direct Graduate Medical Education (GME) and indirect (IME) payments that CMS is proposing to implement.

**Distribution of Additional Residency Positions Due to the CAA** (*DISPLAY pages 1,070 – 1,098*): CMS is proposing to add 200 GME-funded FTEs to the program in FFY 2023 with an additional 200 added in each subsequent year until a total of 1,000 FTEs have been added. Hospitals are proposed to be limited to at most 1.0 full time equivalent position per hospital per year, with no hospital receiving more than 25 FTEs over the course of the program, and each resident must have at least 50 percent of their training time occur at locations that serve underserved populations. Priority for these positions is given in 4 statutorily-specified categories with each category receiving at least 10% of the aggregate of the total residency positions:

- Hospitals located outside of an Urban CBSA;
- Hospitals with a reference resident level greater than the otherwise applicable resident limit;
- States with new medical schools or additional locations/branch campuses.
  - List of states included can be found on *DISPLAY* pages 1080-1081; and
- Hospitals that serve areas that are designated "Health Professional Shortage Areas (HPSA)". For this category CMS proposes to use geographic HPSAs rather than facility HPSAs. HPSAs can be located using the HPSA find tool at <https://data.hrsa.gov/tools/shortage-area/hpsa-find>.

CMS proposes that the application deadline for these positions for a fiscal year be January 31 of the prior fiscal year, starting with January 31, 2022 for positions for FFY 2023.

**Promoting Rural Hospital GME Funding Opportunity** (*DISPLAY pages 1,098 – 1,118*): In order to assist in hospitals raising their FTE cap, and in accordance with the CAA, CMS is proposing that each time an urban hospital and a rural hospital establish a rural training track (RTT) for the first time, both hospitals may receive a rural track FTE limitation. CMS is also proposing that if participating urban and rural hospitals expand a qualifying RTT, that a cap increase would be allowed for both hospitals, with limitations.

**Addressing Adjustment of Low Per Resident Amounts (Direct GME) and Low FTE Resident Caps (Direct GME and IMR) for Certain Hospitals** (*DISPLAY 1,119 – 1,131*): In the past, some hospitals inadvertently limited their ability to receive funding for residents in a new training program due to having accepted residents that rotated from another training program, typically for a short duration. CMS proposes for hospitals that meet certain criteria and have very small FTE resident caps (Category A and B hospitals), that to redetermine the per-resident amount (PRA) "*the training occurring at a Category A Hospital or a Category B Hospital need not necessarily be training residents in a new program; the residents may be in either an approved program that is "new" for Medicare IME and direct GME purposes, or may be in an existing approved program,*" pending determination if each hospital trains the requisite number of FTEs (at least 1.0 for Category A and at least 3.0 for Category B) and the training period occurs in a cost reporting period beginning on or after December 27, 2020 (date of enactment) and before December 26, 2025 (5 years after enactment), regardless of any FTEs are trained prior to December 27, 2020.

To calculate the replacement PRA, CMS is proposing to use the first cost reporting period on or after December 27, 2020 in which a Category A or B hospital trains their requisite FTEs as the PRA base period. The replacement PRAs are then proposed to the lower of:

- “The hospital’s actual cost per resident incurred in connection with the GME program(s) based on the cost and resident data from the hospital’s replacement base year cost reporting period ; and
- The updated weighted mean value of per resident amounts of all hospitals located in the same geographic wage area is calculated using all per resident amounts (including primary care and obstetrics and gynecology and nonprimary care) and FTE resident counts from the most recently settled cost reports of those teaching hospitals.

CMS is proposing to establish a PRA for instances where a hospital trains less than 1.0 FTE and that hospital entered into a GME affiliation agreement for that training. If a hospital did not enter into such an agreement, a PRA will only be established if at least 1.0 FTE is trained. Additionally, CMS proposes that all hospitals, even those not classifying as Category A or B, enter FTE counts on Worksheets E, Part A and E-4 of the CMS-Form-2552-10, for cost reporting periods on or after December 27, 2020 during which the hospital trains at least 1.0 FTE and provide the information required by the Interns and Residents Information System (IRIS), regardless of whether or not the hospital incurs costs or is a program sponsor.

**Hospitals Qualifying to Reset their FTE Resident Caps (DISPLAY pages 1,128 – 1,130):** For Category A and Category B hospitals, CMS proposes that FTE resident caps would only be reset when the hospital “begins training” FTE residents, with “begins training” being defined as “future training in a new program for the first time on or after enactment.”

The Indirect Medical Education adjustment factor is proposed to remain at 1.35 for FFY 2022.

## Updates to the MS-DRGs

DISPLAY pages 19-21, 50 – 777, 1,147 – 1,151, and 1,666

Each year CMS updates the MS-DRG classifications and relative weights to reflect changes in treatment patterns, technology, and any other factors that may change the relative use of hospital resources. CMS typically uses the MedPAR claims data file for IPPS rate-setting that contains claims from discharges 2 years prior to the fiscal year that is the subject of rulemaking. For Hospital Cost Report data, CMS traditionally uses the dataset containing cost reports beginning 3 years prior to the fiscal year under study. CMS evaluated whether this method is still applicable for FFY 2022 and determined that both the FFY 2020 MedPAR claims data and the FFY 2019 Hospital Cost Report data have been significantly impacted by the COVID-19 PHE. Therefore, CMS is proposing to use the FFY 2019 MedPAR claims data and FFY 2018 Hospital Cost Report data in situations where the utilization patterns in the FFY 2020 MedPAR data were significantly impacted by COVID-19 PHE for the FFY 2022 IPPS rate setting. As an alternative, CMS is considering using FFY 2020 MedPAR claims and FFY 2019 Hospital Cost Report Data and made a file available a file on the CMS websites that compares the two approaches to assist with public comment.

The total number of payable DRGs would be held constant at 765, with 98% of DRG weights changing by less than +/- 5%, and 0.5% changing by +/- 10% or more. The five MS-DRGs with the greatest year-to-year change in weight are:

MS-DRG	Final FFY 2021 Weight	Proposed FFY 2021 Weight	Percent Change
MS-DRG 218: CARDIAC VALVE AND OTHER MAJOR CARDIOTHORACIC PROCEDURES WITH CARDIAC CATHETERIZATION WITHOUT CC/MCC	5.1432	6.1165	+18.9%
MS-DRG 014: ALLOGENEIC BONE MARROW TRANSPLANT	12.7788	10.6726	-16.5%
MS-DRG 228: OTHER CARDIOTHORACIC PROCEDURES WITH MCC	6.2153	5.3326	-14.2%
MS-DRG 229: OTHER CARDIOTHORACIC PROCEDURES WITHOUT MCC	3.988	3.4422	-13.7%
MS-DRG 293: HEART FAILURE AND SHOCK WITHOUT CC/MCC	0.6526	0.5900	-9.6%

When CMS reviews claims data, they apply the following criteria to determine if the creation of a new complication or comorbidity (CC) or major complication or comorbidity (MCC) subgroup within an MS-DRG is needed, a subgroup must meet all five criteria in order to warrant being created:

- a 3% reduction in the variance of costs;
- at least 5% of patients in the MS-DRG fall within the subgroup
- 500 or more cases are in the subgroup;
- average costs between the subgroups show at least a 20-percent difference; and
- there is a \$2,000 difference in average costs between subgroups.

Beginning in FFY 2021 CMS expanded these criteria to also include Non-CC subgroups with the belief that this would better reflect resource stratification and promote stability of MS-DRG relative weights by avoiding low volume counts for the Non-CC level MS-DRGs. In this proposed rule, CMS found that applying this criteria to all MS-DRGs currently split into three severity levels for FFY 2022 would result in the deletion of 96 MS-DRGs (32 MS-DRGS multiplied by 3 severity levels) and the creation of 58 new MS-DRGs. These updates would also have an impact on relative weights and payments rates proposed for FFY 2022. Due to the PHE and concerns about the impact that implementing this many MS-DRG changes at one time, CMS is proposing to delay the application of the Non-CC subgroup criteria for these MS-DRGs until FFY 2023 and in the meantime maintain the current structure for FFY 2022.

The full list of proposed FFY 2022 DRGs, DRG weights, and flags for those subject to the post-acute care transfer policy are available in Table 5 on the CMS website at <https://www.cms.gov/files/zip/fy2022-ippms-nprm-table-5.zip>. For comparison purposes, the FFY 2020 DRGs are available in Table 5 on the CMS website at <https://www.cms.gov/files/zip/fy-2021-ippms-fr-table-5.zip>.

- **Chimeric Antigen Receptor (CAR) T-Cell Therapies** (*DISPLAY pages 72 – 74, 280 – 285, and 1,149 – 1,151*): CAR T-cell treatments are eligible for new technology add-on payments since FFY 2020. There had been a request to create a new MS-DRG specifically for CAR T-cell treatments, however CMS has not made any changes due to the limited number of cases in which they are used, and as a result would have made the creation of a CAR T-cell therapy-specific MS-DRG appear premature.

In the FFY 2021 final rule, CMS assigned cases reporting ICD-10-PCS procedure codes XW033C3 or XW043C3 to a new MS-DRG 018 (Chimeric Antigen Receptor (CAR) T-cell Immunotherapy). As additional procedure codes for CAR-T cell therapies are created, CMS will use its established process to assign these procedure codes to the most appropriate MS-DRG. For FFY 2022, the proposed new codes assigned to MS-DRG 018 can be found in Table 6B. CMS is also proposing to revise the title of MS-DRG 018 to “Chimeric Antigen Receptor (CAR) T-cell and Other Immunotherapies” to better reflect other immunotherapies that would be assigned to this MS-DRG.

As providers do not typically pay for the cost of a drug for clinical trials, CMS proposes to apply an adjustment to the payment amount for clinical trial cases that would group to MS-DRG 018, similarly to FFY 2021. The proposed adjustment of 0.17 would be applied to the payment amount for clinical trial cases that would both group to MS-DRG 018 and include ICD-10-CM diagnosis code Z00.6, contain standardized drug charges of less than \$373,000, or when there is expanded access use of immunotherapy. As in the past, CMS would not apply this payment adjustment to cases where a CAR T-cell therapy product is purchased but the case involves a clinical trial of a different product as well as where there is expanded use of immunotherapy.

- **New Technology** (*DISPLAY pages 19-20 and 286 – 777*): CMS states that numerous new medical services or technologies are potentially eligible for add-on payments outside the PPS. Due to the circumstances around FFY 2022 rate setting and the COVID-19 PHE, CMS is proposing to make a one-time exception to continue add-on payments for all technologies approved for payment in FFY 2021, but would otherwise be discontinued in FFY 2022 due to the technologies no longer being considered new. A table of these 14 technologies can be found on Display pages 309-312.

CMS finalized in FFY 2021 that beginning with applications submitted for new technology add-on payments for FFY 2022, CMS could grant conditional approval for new technology add-on payments for those that meet the new technology add-on payment criteria under the alternative pathway for QIDPs or LDAP, even if it has not yet received FDA marketing authorization by July 1 (the existing deadline by which it must be granted FDA marketing authorization to be eligible for new technology add-on payment) of the fiscal year for which the applicant is applying for the add-on payments. CMS seeks public comment on the implementation of 21 new technology add-

on payments under the traditional pathway and 16 under the alternative pathway.

CMS previously established the New COVID-19 Treatments Add-on Payment (NCTAP) to increase the current IPPS payment amount for drugs and biologicals authorized for emergency use for the treatment of COVID-19 in the inpatient setting. Specifically, beginning for discharges on or after November 2, 2020 through the end of the PHE, hospitals will be paid the lesser of 65% of the operating outlier threshold for the claim or 65% of the amount which the cost of the case exceed the standard DRG payment, including the relative weight CARES Act adjustment.

In this rule, CMS is proposing that any discharges which qualify for NCTAP should remain eligible for the add-on for the remainder of the fiscal year following the end of the PHE in order to minimize payment disruption. The extension of NCTAP is also being proposed through the end of the fiscal year the PHE ends for eligible products that are not otherwise approved for new technology add-on. If an eligible product is approved for the new technology add-on for FFY 2022, the NCTAP will be discontinued.

- **Market-Based MS-DRG Relative Weight Data Collection and Change in Methodology for Calculating MS-DRG Relative Weights - Repeal** (*DISPLAY pages 1,147-1,148*): In FFY 2021, CMS finalized a policy that required hospitals to use the Medicare cost report to report “the median payer-specific negotiated charge that the hospital has negotiated with all of its Medicare Advantage (MA) organizations ... payers, by MS-DRG” for cost reporting periods ending on or after January 1, 2021 as well as a new market-based methodology for estimating the MS-DRG relative weights, beginning in FFY 2024, which would be based on the median payer-specific negotiated charge information collected on the Medicare cost report. Due to comments received on the 60-day Paperwork Reduction Act revision request published on November 19, 2020, CMS is proposing to repeal both of the aforementioned policies while comments and alternative approaches are considered.

## Low-Volume Hospital Adjustment

*DISPLAY pages 894 – 899*

Legislative action by Congress over the past several years mandated changes to the low-volume hospital adjustment criteria, allowing more hospitals to qualify for the adjustment and modifying the amount of the adjustments. The Bipartisan Budget Act of 2018 had extended the relaxed low volume adjustment criteria (>15-road miles/ <1,600 Medicare discharges), through the end of FFY 2018. In addition, the Act included a further extension of the adjustment for FFYs 2019-2022 with a change to the discharge criteria by requiring that a hospital have less than 3,800 total discharges (rather than 1,600 Medicare discharges). The current payment adjustment formula for hospitals with between 500 and 3,800 total discharges is:

$$\text{Low Volume Hospital Payment Adjustment} = \frac{95}{330} - \frac{\text{Total Discharges}}{13,200}$$

Beginning with FFY 2023, the criteria for the low-volume hospital adjustment will return to the more restrictive levels. At that point, in order to receive a low-volume adjustment, subsection (d) hospitals would need to meet the following criteria:

- Be located more than 25 road miles from another subsection (d) hospital; and
- Have fewer than 200 total discharges (All Payer) during the fiscal year.

In order for a hospital to acquire low-volume status for FFY 2022, consistent with historical practice, CMS is proposing to continue the requirement that a hospital must submit a written request for low-volume hospital status to its MAC that includes sufficient documentation to establish that the hospital meets the applicable mileage and discharge criteria. The MAC must receive a written request by September 1, 2021 in order for the adjustment to be applied to payments for its discharges beginning on or after October 1, 2021. If accepted, the adjustment will be applied prospectively within 30 days of low-volume hospital determination.

Under this process, a hospital receiving the adjustment for FFY 2021 may continue to receive it without reapplying if it continues to meet the mileage and discharge criteria.

## RRC Status

*DISPLAY pages 887 - 893*

Hospitals that meet a minimum case-mix and discharge criteria (as well as one of 3 optional criteria relating to specialty composition of medical staff, source of inpatients, or referral volume) may be classified as Rural Referral Centers (RRCs). This special status provides an exemption from the 12% rural cap on traditional DSH payments and exemption from the proximity criteria when applying for geographic reclassification. Each year, CMS updates the minimum case-mix index and discharge criteria related to achieving RRC status (for hospitals that cannot meet the minimum 275 bed criteria). The proposed FFY 2022 minimum case-mix and discharge values are available on the pages listed above.

CMS notes that the CMI values calculated using FFY 2019 data differ greatly from those calculated using FFY 2020. As such, CMS is proposing to calculate CMI values for FFY 2022 using discharge data from FFY 2019 and including bills posted to CMS' records through March 2020.

## Medicare Shared Savings Program

*DISPLAY pages 1,558 – 1,565*

Due to the COVID-19 PHE and concerns about lack of predictability and disrupted population health activities brought forth by Accountable Care Organizations (ACOs) participating in the BASIC track, CMS is proposing that those participating ACOs may elect to maintain or “freeze” their risk level under the BASIC track’s glide path for performance year (PY) 2022 at the same level which it participated during PY 2021. This is similar to the provision granted to ACOs in the May 2020 COVID-19 IFC.

For PY 2023, an ACO that opted for this advancement deferral would automatically advance to the level of the track’s glide path it would have participated in for PY 2023 if it had advanced normally in PY 2022 (unless the ACO elects to advance more quickly before the start of PY 2023). ACOs that participated in the freeze for PY 2021 and PY 2022 would be similarly advanced for PY 2023. The table on DISPLAY page 1,564 shows the different glide path scenarios for each if an ACO elected to maintain their levels.

## Quality-Based Payment Adjustments

*DISPLAY pages 958 – 1,067*

For FFY 2022, IPPS payments to hospitals will be adjusted for quality performance under the Value Based Purchasing (VBP) Program, Readmissions Reduction Program (RRP), and the Hospital-Acquired Conditions (HAC) Reduction Program. Detail on the FFY 2022 programs and payment adjustment factors are below (future program year program changes are addressed in the next section of this brief):

- **VBP Adjustment** (*DISPLAY pages 992 – 1,047*): The FFY 2022 program will include hospital quality data for 21 measures in 4 domains: safety; clinical outcomes; person and community engagement; and efficiency and cost reduction. By law, the VBP Program must be budget neutral and the FFY 2022 program will be funded by a 2.0% reduction in IPPS payments for hospitals that meet the program eligibility criteria (estimated at \$1.9 billion). Because the program is budget neutral, hospitals can earn back some, all, or more than their 2.0% reduction.

In the August 25th COVID-19 interim final rule with comment period (IFC), CMS updated the extraordinary circumstances exception policy in response to the public health emergency so that no claims data or chart-abstracted data reflecting services provided January 1, 2020 - June 30, 2020 will be used in calculations for the VBP Program. This was **not** extended for Q3 and Q4 of 2020.

CMS is proposing to suppress measures for the FFY 2022 VBP and therefore not adjust hospital payments for the program year (detailed below). While the proposals are not finalized, CMS has calculated and published proxy factors based on the current year’s (FFY 2021) program. Hospitals should use caution in reviewing these factors as they do not reflect updated performance periods/standards, nor changes to hospital eligibility.

The proxy factors published with the proposed rule are available in Table 16A on the CMS website at <https://www.cms.gov/files/zip/fy2022-ipp-rrp-table-16.zip>.

Details and information on the program currently in place for FFY 2020 and FFY 2021 program are available on CMS' QualityNet website at <https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1228772039937>.

- **Readmissions Reduction Program (RRP)** (*DISPLAY pages 958 – 991*): The FFY 2022 RRP will evaluate hospitals on 6 conditions/procedures: acute myocardial infarction (AMI), heart failure (HF), pneumonia (PN), chronic obstructive pulmonary disease (COPD), elective total hip arthroplasty (THA) and total knee arthroplasty (TKA), and coronary artery bypass graft (CABG). The RRP is not budget neutral; hospitals can either maintain full payment levels or be subject to a penalty of up to 3.0%.

In accordance with the August 25<sup>th</sup> COVID-19 IFC, no claims data reflecting services provided January 1, 2020 - June 30, 2020 will be used in calculations for RRP. Therefore, the FFY 2022 RRP will only use data from July 1, 2017-December 31, 2019 for calculations. This was **not** extended for Q3 and Q4 of 2020.

Hospitals are grouped into peer groups (quintiles) based on their percentage of full-benefit dual eligible patients as a ratio of total Medicare Fee-For-Service and Medicare Advantage patients during the same 3-year period as the program performance period. Hospital excess readmission ratios are compared to the median excess readmission ratio of all hospitals within their quintile for each of the 6 measures. A uniform modifier is applied such that the adjustment is budget neutral nationally.

The data applicable to the FFY 2022 RRP program is still being reviewed and corrected by hospitals, and therefore CMS did not yet post factors for the FFY 2022 program in Table 15. CMS expects to release the final FFY 2022 RRP factors in the fall of 2021.

Details and information on the RRP currently are available on CMS' QualityNet website at <https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1228772412458>.

- **HAC Reduction Program** (*DISPLAY pages 1,048 – 1,067*): The FFY 2022 HAC program will evaluate hospital performance on 6 measures: the AHRQ Patient Safety Indicator (PSI)-90 (a composite of 10 individual HAC measures), Central Line-Associated Bloodstream Infection (CLABSI) rates, Catheter-Associated Urinary Tract Infection (CAUTI) rates, the Surgical Site Infection (SSI) Pooled Standardized Infection Ratio, Methicillin-resistant Staphylococcus Aurea (MRSA) rates, and Clostridium difficile (C.diff.) rates. The HAC Reduction Program is not budget neutral; hospitals with a total HAC Score that falls within the worst performing quartile for all eligible hospitals will be subject to a 1.0% reduction in IPPS payments. Total HAC scores are calculated by applying an equal weight to each measure for which a hospital has a score.

Adopted in the August 25<sup>th</sup> COVID-19 IFC, no claims and chart-abstracted data reflecting services provided January 1, 2020 - June 30, 2020 will be used in calculations for the HAC Reduction Program. Some data reporting has been made optional as well. Please refer to CMS-3401-IFC for details. This was **not** extended for Q3 and Q4 of 2020.

CMS uses a continuous z-score methodology for HAC which eliminates ties in the program and enhances the ability to distinguish low performers from top performers.

Details and information on the HAC currently are available on CMS' QualityNet website at <https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1228774189166>.

## Quality-Based Payment Policies—FFYs 2023 and Beyond

For FFYs 2023 and beyond, CMS is proposing new policies for its quality-based payment programs.

For all of the quality-based payment programs, CMS is proposing the following measure suppression factors to determine whether to suppress a measure in the program for one or more years that overlap with the COVID-19 PHE:

- *“Significant deviation in national performance on the measure during the PHE for COVID-19, which could be significantly better or significantly worse compared to historical performance during the immediately preceding program years.*
- *Clinical proximity of the measure’s focus to the relevant disease, pathogen, or health impacts of the PHE for COVID-19.*
- *Rapid or unprecedented changes in: (i) clinical guidelines, care delivery or practice, treatments, drugs, or related protocols, or equipment or diagnostic tools or materials; or (ii) the generally accepted scientific understanding of the nature or biological pathway of the disease or pathogen, particularly for a novel disease or pathogen of unknown origin.*
- *Significant national shortages or rapid or unprecedented changes in: (i) healthcare personnel; (ii) medical supplies, equipment, or diagnostic tools or materials; or (iii) patient case volumes or facility-level case mix.”*

Additionally for all programs, CMS is requesting comment on the creation of a measure suppression policy in preparation for a future national PHE and if such policy should have the flexibility to suppress certain measures outside of the rulemaking process. CMS is also looking for feedback on whether a regional adjustment should be included in the measure suppression policy.

- **VBP Program—FFYs 2022 through 2025 (DISPLAY pages 992 – 1,047):** CMS has already adopted VBP program rules through FFY 2022 and some program policies and rules beyond FFY 2022. CMS is proposing further program updates through FFY 2027, which include:

- National performance standards for a subset of the FFYs 2024 and 2027 program measures (performance standards for other program measures for future program years will be put forward in future rulemaking).

Due to the impact of the COVID-19 PHE, CMS is proposing the following:

- Omit all measures in the Person and Community Engagement, Safety, and Efficiency and Cost Reduction domains for FFY 2022;
- Adopt a special scoring and payment rule for FFY 2022 that calculates measure rates for all measures, but only achievement/improvement/domain scores for the Clinical Outcomes domain. These scores would be solely for information purposes as all hospitals would be given a value-based incentive payment amount that leaves base operating DRG payments unchanged for FFY 2022;
- Omit the MORT-30-PN measure for the FFY 2023 program;
- Exclude COVID-19 diagnosed patients from the denominators for the Clinical Outcomes domain measures beginning with the FFY 2023 program; and
- Update baseline periods for the FFY 2024 program for Person and Community Engagement, Safety, and Efficiency and Cost Reduction domains from Calendar Year (CY) 2020 to CY 2019.

CMS would still provide FFY 2022 confidential feedback reports to hospitals to allow review of changes in performance rates that CMS has observed (possibly after August 1, 2021 due to data submission extensions). CMS also would still publically report Q3 and Q4 2020 data noting the limitations of the data.

Separately, CMS is proposing to remove the Patient Safety and Adverse Events Composite (PSI-90) measure (NQF #0531) measure from the VBP program beginning with FFY 2023 (and therefore the measure would no longer be added into the program) due to the cost associated with the measure outweighing the benefit of its use in the program.

- **Readmissions Reduction Program (DISPLAY pages 958 – 991):** CMS is proposing an automatic adoption of the use of MedPAR data for the measure 3-year performance period beginning FFY 2023 and for all subsequent program years, unless otherwise specified.

Due to the impact of the COVID-19 PHE, CMS is proposing the following:

- Omit the Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) following Pneumonia Hospitalization measure (NQF #0506) from the FFY 2023 program (measure would be weighted at 0%); and
- Exclude COVID-19 diagnosed patients from the measure denominators for the remaining 5 conditions beginning with the FFY 2023 program.

In addition, CMS is making several clarifications for the current Extraordinary Circumstance Exception (ECE) Policy.

Lastly, CMS is requesting comment on possible future stratification of condition/procedure-specific readmission measure results by race/ethnicity, and the collection of additional social risk factors (ex. Language preference, disability status). Specifically CMS is suggesting providing confidential hospital specific reports for the 6 readmission measures stratified by both dual eligible (as done previously) and race/ethnicity in Spring 2022, with publication of the results in Spring 2023.

CMS also seeks comment on mechanisms for incorporating other demographic characteristics to address and advance health equity, including the potential to include administrative and self-reported data to measure co-occurring disability status.

- **HAC Reduction Program—FFY 2021** (*DISPLAY pages 1,048 – 1,067*): CMS is proposing to suppress 3Q2020 and 4Q2020 (July 1, 2020 through December 31, 2020) PSI-90 and CDC NHSN HAI measure data from the HAC program for FFY 2022 and FFY 2023 due to the COVID-19 PHE. Therefore, with the previously finalized omission of January 1, 2020 - June 30, 2020 data from the program, this would result in the following performance periods:
  - FFY 2022: PSI-90 from July 1, 2018 – December 31, 2019, HAI from January 1, 2019 – December 31, 2019; and
  - FFY 2023: PSI-90 from July 1, 2019 – December 31, 2019 and January 1, 2021 – June 30, 2021, HAI from January 1, 2021 – December 31, 2021.

Hospitals would still be required to submit 3Q2020 and 4Q2020 data and data would still be publicly reported. CMS would also still include 3Q and 4Q 2020 in feedback reports to hospitals for information purposes.

Separately, CMS is making several clarifications for the current ECE Policy.

## **Updates to the IQR Program and Electronic Reporting Under the Program**

*DISPLAY pages 1,261– 1,372*

CMS is proposing to adopt five new measures into the IQR program:

- Maternal Morbidity Structural Measure for CY 2021 reporting period/FFY 2023 payment determination beginning with a shortened reporting period from October 1, 2021 - December 31, 2021;
- Hybrid Hospital-Wide All-Cause Risk Standard Mortality (Hybrid HWM) - beginning with a voluntary submission period which would run from July 1, 2022 - June 30, 2023 followed by mandatory reporting for the FFY 2026 payment determination beginning with July 1, 2023 - June 30, 2024;
- COVID-19 Vaccination Coverage Among Healthcare Personnel (HCP) for CY 2021 reporting period/FFY 2023 payment determination beginning with a shortened reporting period from October 1, 2021 - December 31, 2021;
- Hospital Harm-Severe Hypoglycemia eCQM beginning with the CY 2023 reporting period/FFY 2025 payment determination; and
- Hospital Harm-Severe Hyperglycemia eCQM beginning with the CY 2023 reporting period/FFY 2025 payment determination.

CMS is proposing to remove one measure from IQR beginning with the CY 2021 reporting period/FFY 2023 payment determination:

- Death Among Surgical Inpatients with Serious Treatable Complications (CMS PSI-04).

CMS is also proposing to remove three measures from IQR beginning with the CY 2024 reporting period/FFY 2026 payment determination:

- Exclusive Breast Milk Feeding (PC-05) (NQF #0480);
- Admit Decision Time to ED Departure Time for Admitted Patients (ED-2);
- Anticoagulation Therapy for Atrial Fibrillation/Flutter (STK-03); and
- Discharged on Statin Medication (STK-06).

CMS is seeking comment on the potential of the following new measures for the IQR program:

- 30-Day, All-Cause Mortality Measure for Patients Admitted With COVID-19 Infection; and

- Hospital-Level, Risk Standardized Patient Reported Outcomes Measure Following Elective Primary Total Hip and/or Total Knee Arthroplasty.

In addition, CMS has identified several opportunities in which the IQR program could address the gap in existing health inequities including the stratification of HWR measure data by both dual eligibility and race/ethnicity as well as the inclusion of a structural measure assessing the degree of hospital leadership engagement in health equity performance data.

In the FFY 2021 final rule, CMS finalized a progressive increase, over a 3-year period, to the number of quarters for which hospitals are required to report eCQM data up to four quarters of data. Until hospitals are required to submit 4 calendar quarters of self-selected data, the quarters chosen can either be consecutive or nonconsecutive. The transition is outlined below.

Reporting Period/Payment Determination	Finalized # of Self-Selected Calendar Quarters Required	Finalized # of Self-Selected eQMs required
CY 2021 reporting period/FFY 2023 payment determination	2	4
CY 2022 reporting period/FFY 2024 payment determination	3	3 and Safe Use of Opioids eCQM
CY 2023 reporting period/FFY 2025 payment determination	4	

In the CY 2021 Payment Policies Under the Physician Fee Schedule Final Rule, CMS expanded flexibility under Hospital IQR Program by allowing hospitals to use either technology certified to the 2015 Edition criteria for CEHRT as was previously finalized for reporting eQMs and for reporting hybrid measures, or technology certified to the 2015 Edition Cures Update standards. In this proposed rule, CMS is proposing to require hospitals to use only certified technology updated consistent with the 2015 Edition Cures Update to submit data for the IQR program, beginning CY 2023 reporting period/FFY 2025 payment determination.

In the FFY 2021 IPPS final rule, CMS finalized policies to combine the validation process for chart-abstracted measure data and eCQM data using an incremental approach, which included updating the educational review process to address eCQM validation results. In this proposed rule, CMS is proposing to extend the effects of the education review process policy beginning with validations affecting the FFY 2024 payment determination so that scores can be corrected for all four quarters of validation.

Tables in the proposed rule on *Display* pages 1,327 – 1,330 outline the previously adopted and newly proposed Hospital IQR Program measure set for the FFYs 2023 – 2026 payment determination and subsequent years.

In the CY 2021 OPPI/ASC final rule, CMS adopted modifications to the methodology used to calculate the Overall Hospital Quality Star Rating. The Overall Star Rating will continue to use data collected on hospital inpatient and outpatient measures that are publicly reported on Care Compare through CMS quality programs, including data from the Hospital IQR Program.

## **Request for Information – Advancing to Digital Quality Measurement and the Use of Fast Healthcare Interoperability Resources (FHIR) in Hospital Quality Programs**

*DISPLAY pages 1,222 – 1,239*

CMS aims to move to fully digital quality measurement in quality reporting and value-based purchasing programs by 2025. CMS has heard from stakeholders about the technological challenges and burden of reporting eCQM data and therefore is currently working to convert current eQMs to FHIR. CMS is specifically looking for feedback on its potential use of FHIR, a free and open source standards framework, to define digital quality measures (dQMs) within hospital quality programs.

CMS is also requesting feedback on the following definition of dQMs and how it can be elaborated to define dQMs as a software that processes digital data to produce a measure score or measure scores: “sources of health information that are captured and can be transmitted electronically via interoperable systems.”

To enable the transition from eQMs to dQMs and FHIR, CMS is looking for feedback on its consideration to modernize the quality measurement enterprise in four ways:

- *“Leverage and advance standards for digital data and obtain all EHR data required for quality measures via provider FHIR-based APIs;*
- *Redesign our quality measures to be self-contained tools;*
- *Better support data aggregation; and*
- *Work to align measure requirements across our reporting programs, other Federal programs and agencies, and the private sector where appropriate.”*

Several other areas identified for comment are listed on *Display* pages 1,237 – 1,238.

## **Request for Information – Closing the Health Equity Gap in CMS Hospital Quality Programs**

*DISPLAY pages 1,239– 1,261*

CMS is requesting public comment on potential expansion of current disparity methods in hospital quality programs. CMS states it is committed to achieving equity in health care outcomes and supporting providers in quality improvement activities to reduce health inequities.

Specifically, CMS is seeking comment on several items listed on *Display* pages 1,259 – 1,261.

## **Promoting Interoperability Program**

*DISPLAY pages 1,431 – 1,491*

The Medicaid Promoting Interoperability Program is ending CY 2021 and therefore December 31, 2021 is the last date that States can make program incentive payments to Medicaid eligible hospitals (other than pursuant to a successful appeal related to 2021 or a prior year).

For the Medicare Promoting Interoperability Program, CMS is proposing to continuation of an EHR reporting period minimum of any continuous 90-day period for CY 2023 for new and returning participants. For CY 2024, CMS is proposing to increase the EHR reporting period minimum to any continuous 180-day period for new and returning participants. CMS states this would minimally increase burden and the additional data would help to further improve the program.

CMS is proposing that the Query of Prescription Drug Monitoring Program (PDMP) measure remain option but worth 10 bonus points instead of 5, beginning with CY 2022 reporting. This would increase maximum Electronic Prescribing points to 20 for CY 2022. With this, CMS is requesting feedback on requiring the Query of PDMP measure in the near future.

Separately, beginning with CY 2022 reporting, CMS is proposing to adopt the Health Information Exchange (HIE) Bi-Directional Exchange measure as an optional alternative to the two existing Health Information Exchange measures (listed below). Hospitals and CAHs would either need to report the two existing measures OR the new bi-directional exchange measure. The new measure would be worth 40 points. CMS is hoping this optional measure incentivizes eligible hospitals and CAHs *“to participate in HIEs while establishing a high performance standard for sharing information with other health care providers.”*

CMS is also proposing to begin requiring the following four measures of the Public Health and Clinical Data Exchange objective, beginning with CY 2022 reporting, in order to allow nationwide syndromic surveillance for early warning of emerging outbreaks and threats:

- Syndromic Surveillance Reporting ;
- Immunization Registry Reporting;
- Electronic Case Reporting; and
- Electronic Reportable Laboratory Result Reporting.

An eligible hospital or CAH would receive 10 points for the objective if they report a “yes” response for each of the 4 required measures. If a hospital does not report “yes” for each of the 4 measures, the hospital will need to claim applicable exclusions for which they qualify for the remaining measures. Otherwise, they would receive 0 points. If the

hospital or CAH claims applicable exclusions for all four measures, CMS proposes to redistribute the points associated with the Provider to patient Exchange objective.

As for the two other measures in the Provider to patient Exchange objective, CMS proposes to make them optional and available for 5 bonus points if they report a “yes” for either of the measures.

Lastly, CMS is proposing to add a new SAFER Guides measure to the Protect Patient Health Information objective beginning with CY 2022 EHR reporting with a “yes/no” response that would not impact the score of the Medicare Promoting Interoperability Program.

Proposed Performance-Based Scoring Methodology Beginning with EHR Reporting Periods in CY 2022:

Objectives	Measures	2022: Maximum Points
Electronic Prescribing	e-Prescribing	10 points
	Query of Prescription Drug Monitoring Program (PDMP)	10 points (bonus) <b><i>(proposed)</i></b>
Health Information Exchange	Support Electronic Referral Loops by Sending Health Information	20 points
	Support Electronic Referral Loops by Receiving and Reconciling Health Information	20 points
	<b>OR</b>	
	Health Information Exchange (HIE) Bi-Directional Exchange measure	40 points (optional instead of previous 2 measures) <b><i>(proposed)</i></b>
Provider to Patient Exchange	Provide Patients Electronic Access to Their Health Information	40 points
Public Health and Clinical Data Exchange	<u>Proposed as required with yes/no response</u> Syndromic Surveillance Reporting Immunization Registry Reporting Electronic Case Reporting Electronic Reportable Laboratory Result Reporting	10 points <b><i>(proposed)</i></b>
	<u>Proposed as optional to report one of the following</u> Public Health Registry Reporting Clinical Data Registry Reporting	5 points (bonus) <b><i>(proposed)</i></b>

With regards to the scoring methodology, CMS is proposing to increase the minimum scoring threshold from 50 points to 60 points (out of 100 points) beginning with CY 2022.

In addition, CMS is proposing to modify the Provide Patients Electronic Access to Their Health Information measure beginning with the CY 2022 reporting period to add a data availability requirement. Specifically, hospitals and CAHs will have to ensure that the patient health information remains available to the patient (or patient-authorized representative) to access indefinitely.

Beginning with CY 2022 reporting, CMS is proposing to eliminate 2 of the 3 attestation statements that require a hospital demonstrates that the hospital has not knowingly and willfully taken action to limit or restrict the compatibility or interoperability of the certified EHR technology.

Consistent with the Hospital IQR program, CMS is proposing to remove four eQMs and adopt two new eQMs from the Hospital IQR programs measure set. These are listed in the IQR section of this brief.

Also to align with the changes to IQR, CMS is proposing to require hospitals to use only certified technology updated consistent with the 2015 Edition Cures Update to submit data for eQMs, beginning CY 2023 reporting period.